Institution
Tenri Hospital
Healthcare•Tenri, Japan•
About: Tenri Hospital is a healthcare organization based out in Tenri, Japan. It is known for research contribution in the topics: Percutaneous coronary intervention & Heart failure. The organization has 1335 authors who have published 1877 publications receiving 33842 citations.
Topics: Percutaneous coronary intervention, Heart failure, Myocardial infarction, Hazard ratio, Aortic valve replacement
Papers published on a yearly basis
Papers
More filters
••
TL;DR: HypoFXSRT with a BED of less than 180 Gy was almost safe for stage I NSCLC, and the local control and overall survival rates in 5 years with a AED of 100 Gy or more were superior to the reported results for conventional radiotherapy.
880 citations
••
TL;DR: Stereotactic irradiation has been actively performed using various methods to achieve better local control of Stage I nonsmall cell lung carcinoma in Japan and results from a Japanese multiinstitutional study are retrospectively evaluated.
Abstract: BACKGROUND
Stereotactic irradiation (STI) has been actively performed using various methods to achieve better local control of Stage I nonsmall cell lung carcinoma (NSCLC) in Japan. The authors retrospectively evaluated results from a Japanese multiinstitutional study.
METHODS
Patients with Stage I NSCLC (n = 245; median age, 76 years; T1N0M0, n=155; T2N0M0, n=90) were treated with hypofractionated high-dose STI in 13 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. A total dose of 18–75 gray (Gy) at the isocenter was administered in 1–22 fractions. The median calculated biologic effective dose (BED) was 108 Gy (range, 57–180 Gy).
RESULTS
During follow-up (median, 24 months; range, 7–78 months), pulmonary complications of National Cancer Institute-Common Toxicity Criteria Grade > 2 were observed in only 6 patients (2.4%). Local progression occurred in 33 patients (14.5%), and the local recurrence rate was 8.1% for BED ≥ 100 Gy compared with 26.4% for < 100 Gy (P < 0.05). The 3-year overall survival rate of medically operable patients was 88.4% for BED ≥ 100 Gy compared with 69.4% for < 100 Gy (P < 0.05).
CONCLUSIONS
Hypofractionated high-dose STI with BED < 150 Gy was feasible and beneficial for curative treatment of patients with Stage I NSCLC. For all treatment methods and schedules, local control and survival rates were better with BED ≥ 100 Gy compared with < 100 Gy. Survival rates in selected patients (medically operable, BED ≥ 100 Gy) were excellent, and were potentially comparable to those of surgery. Cancer 2004. © 2004 American Cancer Society.
836 citations
••
TL;DR: Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients and relatively well tolerated in patients with IPF.
Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial was conducted in Japanese patients with well-defined IPF to determine the efficacy and safety of pirfenidone, a novel antifibrotic oral agent, over 52 weeks. Of 275 patients randomised (high-dose, 1,800 mg x day(-1); low-dose, 1,200 mg x day(-1); or placebo groups in the ratio 2:1:2), 267 patients were evaluated for the efficacy of pirfenidone. Prior to unblinding, the primary end-point was revised; the change in vital capacity (VC) was assessed at week 52. Secondary end-points included the progression-free survival (PFS) time. Significant differences were observed in VC decline (primary end-point) between the placebo group (-0.16 L) and the high-dose group (-0.09 L) (p = 0.0416); differences between the two groups (p = 0.0280) were also observed in the PFS (the secondary end-point). Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients. Pirfenidone was relatively well tolerated in patients with IPF. Treatment with pirfenidone may decrease the rate of decline in VC and may increase the PFS time over 52 weeks. Additional studies are needed to confirm these findings.
813 citations
••
TL;DR: Hitual consumption of sugar sweetened beverages was associated with a greater incidence of type 2 diabetes, independently of adiposity, and both artificially sweetened alcoholic beverages and fruit juice were unlikely to be healthy alternatives to sugarsweetened beverages for the prevention of type 1 diabetes.
Abstract: ObjeCtives To examine the prospective associations between consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice with type 2 diabetes before and after adjustment for adiposity, and to estimate the population attributable fraction for type 2 diabetes from consumption of sugar sweetened beverages in the United States and United Kingdom. Design Systematic review and meta-analysis. Data sOurC es anD eligibility
768 citations
••
TL;DR: The results suggested that the systemic tissue damage seen in most patients with LGL leukemia and NK–type lymphoma is due to sFasL produced by these malignant cells, and neutralizing anti–FAsL antibodies or matrix metalloproteinase inhibitors may be of use in modulating such tissue damage.
Abstract: The Fas ligand (FasL), a member of the tumor necrosis factor family, induces apoptosis in Fas–bearing cells. The membrane–bound human FasL was found to be converted to a soluble form (sFasL) by the action of a matrix metalloproteinase–like enzyme. Two neutralizing monoclonal anti–human FasL antibodies were identified, and an enzyme–linked immunosorbent assay (ELISA) for sFasL in human sera was established. Sera from healthy persons did not contain a detectable level of sFasL, whereas those from patients with large granular lymphocytic (LCL) leukemia and natural killer (NK) cell lymphoma did. These malignant cells constitutively expressed FasL, whereas peripheral NK cells from healthy persons expressed FasL only on activation. These results suggested that the systemic tissue damage seen in most patients with LGL leukemia and NK–type lymphoma is due to sFasL produced by these malignant cells. Neutralizing anti–FasL antibodies or matrix metalloproteinase inhibitors may be of use in modulating such tissue damage.
713 citations
Authors
Showing all 1337 results
Name | H-index | Papers | Citations |
---|---|---|---|
Tatsuya Sawamura | 77 | 287 | 18881 |
Kazuichi Okazaki | 72 | 588 | 24542 |
Michiaki Mishima | 61 | 496 | 17322 |
Osamu Yoshida | 58 | 461 | 11197 |
Takayuki Nakagawa | 56 | 394 | 10509 |
Hiroshi Kimura | 54 | 308 | 11407 |
Eiji Ishimura | 52 | 244 | 9567 |
Hidenobu Tanihara | 49 | 255 | 7708 |
Akio Niimi | 46 | 285 | 8144 |
Hajime Handa | 42 | 385 | 7028 |
Hisako Matsumoto | 41 | 181 | 5799 |
Hirohiko Yamabe | 41 | 147 | 8565 |
Koji Izutsu | 38 | 233 | 5811 |
Akira Sano | 37 | 142 | 5238 |
Akira Nakajima | 36 | 165 | 4885 |